Docoh
Loading...

Tue. 12 Oct 2021, 6:46am ETBenzinga
In: News, Upgrades, Price Target, Analyst Ratings
JP Morgan analyst Anupam Rama upgrades Protagonist Therapeutics (NASDAQ:PTGX) from Neutral to Overweight and announces $55 price target.